Rediff Logo
Money
Line
Channels: Astrology | Broadband | Contests | E-cards | Money | Movies | Romance | Search | Wedding | Women
Partner Channels: Bill Pay | Health | IT Education | Jobs | Technology | Travel
Line
Home > Money > Business Headlines > Report
July 10, 2001
Feedback  
  Money Matters

 -  Business Special
 -  Business Headlines
 -  Corporate Headlines
 -  Columns
 -  IPO Center
 -  Message Boards
 -  Mutual Funds
 -  Personal Finance
 -  Stocks
 -  Tutorials
 -  Search rediff

    
      



 
 Search the Internet
         Tips
 Sites: Finance, Investment
E-Mail this report to a friend
Print this page

Govt to support R&D efforts of pharma industry

BS Economy Bureau

The Indian pharma industry should carry forward basic research to its logical conclusion and formulate its own brand of success in drug discovery, said minister of state for chemicals and fertilisers, Satya Brate Mookherjee on Monday.

The government will encourage the industry in such ventures, including providing appropriate fiscal and non-fiscal incentives for R&D in the pharma sector, he said at the meeting of the consultative committee of the ministry of chemicals and fertilisers.

The agenda for the meeting was drugs and pharmaceuticals - Vision 2020. Members of Parliament attending the meeting said stress on availability of cheap and effective medicines to a greater section of the population would make it a pro-people vision paper.

He said Indian pharma products should be of a quality that can be benchmarked against international regulatory standards in manufacturing.

It would also be necessary to upgrade the Central Drugs Standard Control Organisation by modernising, restructuring the existing system.

He also said that investment in research and development should be upscaled to10 per cent of sales turnover.

This should be further leveraged through networking with government national labs and academia.

Powered by

YOU MAY ALSO WANT TO READ:
The Rediff-Business Standard Special
The Budget 2001-2002 Special
Money
Business News

Tell us what you think of this report